Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

Bausch + Lomb acquired Whitecap Biosciences, including its two therapies for potential use in glaucoma and geographic atrophy ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target ...

The global vision care products market is projected to reach USD 103.7 billion by 2032, growing at a CAGR of 6.21%. This growth ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

TikTok influencers are mourning the impending shutdown of the popular Chinese-owned social media platform after the Supreme Court upheld a law to ban the application if it is not sold in the ...

The American supermodel, 51, broke down in tears as she revealed she was in Sydney when she learned her lavish Palisades house had burned to the ground. She told Channel Seven hosts Natalie Barr ...

These drops work with the eye's natural tears to help keep your contact lenses feeling fresh and comfortable all day Hydration Boost with Hyaluronate: Our moisturizing eye drops instantly ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...